Oncosec Medical Inc (ONCS) 0.7600 $ONCS PUNIT DHILLON of

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Oncosec Medical Inc (ONCS) 0.7600 $ONCS

PUNIT DHILLON of OncoSec Medical Incorporated (ONCS)-Other O bought Shares of ONCS
M2 - Fri Mar 21, 7:39AM CDT
Reported by InsiderCow.com at 2014-03-20 14:21:26 ET

OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
Business Wire - Mon Mar 17, 5:03AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences on Wednesday, March 19th at 3:00 p.m. (EST).

OncoSec Medical to Evaluate Increased Dose Frequency of ImmunoPulse in Ongoing Phase II Melanoma Trial
Business Wire - Wed Mar 12, 5:02AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that the company has submitted a protocol addendum to the FDA and institutional IRBs to evaluate an increased dose frequency for ImmunoPulse in an expansion of its ongoing Phase II melanoma trial. The Company expects to enroll up to 21 patients in this expansion, and expects two additional key cancer centers as sites participating in this study.

OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
Business Wire - Tue Feb 25, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).

OTC Daily Alert Stock Watch - OncoSec Medical Incorporated (OTCQB: ONCS)
WorldStockWire - Thu Feb 06, 2:45PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

OncoSec Medical to Present at 16th Annual BIO CEO & Investor Conference
Business Wire - Tue Feb 04, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 16th Annual BIO CEO & Investor Conference at the Waldorf Astoria in New York, New York on Monday, February 10 at 4:00 p.m. (EST) in the third floor Basildon Suite.

State of Tech: A Guide to the Q4 2013 Earnings Season that Boldly Predicts the Winners and Losers, Including Covering Teradyne, Sanmina, and Many More
PR Newswire - Fri Jan 17, 7:37AM CST
Next Inning Technology Research (http://www.nextinning.com), an online investment newsletter focused on technology stocks, has issued updated outlooks for Teradyne (NYSE: TER), Sanmina (Nasdaq: SANM), Lattice Semiconductor (Nasdaq: LSCC), Skyworks Solutions (Nasdaq: SWKS) and Towerstream (Nasdaq: TWER).

Princess Cruises Launches Its Most Extensive Marketing Campaign Ever, Inviting Travelers Desiring Meaningful Vacations to "Come Back New"
PR Newswire - Wed Jan 15, 7:00AM CST
As the new year begins, Princess Cruises is launching a fresh advertising campaign to remind travelers that cruising can transform and enrich their lives, and set the line's cruise vacations apart as an opportunity for passengers to "come back new." The $20 million program will be the company's most extensive ever, and marks a return to television and radio advertising for the brand, which has not taken to the airwaves for more than a decade.

OncoSec Medical Announces 2014 Strategic Update
Business Wire - Tue Jan 14, 5:02AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced a strategic update and reported on progress made in 2013. Progress included advancing metastatic melanoma, Merkel cell clinical programs and preclinical combination studies with anti-PD-1, anti-PDL-1, and anti-CTLA4, which highlight a commercial path forward.

OncoSec Medical to Present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference
Business Wire - Mon Jan 13, 5:03AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present at "TEN"; Noble Financial Capital Markets' Tenth Annual Equity Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January 21 at 1:30 p.m. (EST) in Room 1.

Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.
M2 - Fri Jan 10, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/l3xgrw/sezary_syndrome) has announced the addition of the "Sezary Syndrome Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Sezary Syndrome Global Clinical Trials Review, H2, 2013" provides data on the Sezary Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Sezary Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Sezary Syndrome. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Angimmune LLC -Eisai Co., Ltd. -Emergent BioSolutions Inc. -Janssen Global Services, LLC -Kirin Holdings Company, Limited -Merck & Co., Inc. -National Cancer Institute -Northwestern University -OncoSec Medical Inc. -Roswell Park Cancer Institute -Shionogi & Co., Ltd. -Spectrum Pharmaceuticals, Inc. -Stanford University -University of Washington -Wake Forest University For more information visit http://www.researchandmarkets.com/research/l3...y_syndrome About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

OncoSec Medical to Present Corporate Update at Biotech Showcase 2014
Business Wire - Tue Jan 07, 5:03AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a biotechnology company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will provide a corporate update at Biotech Showcase 2014; one of the world's largest life sciences conferences held annually in San Francisco.

OncoSec Medical Announces Positive Interim Data from Phase 2 Study of OMS-I100 in Metastatic Melanoma
Business Wire - Mon Dec 16, 5:02AM CST
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced positive interim data from its ongoing Phase 2 trial of OMS-I100 in the treatment of metastatic melanoma. The results were presented by principal investigator Adil Daud, MD, at the Advances in Cancer Immunotherapy meeting at the University of California San Francisco.

OncoSec Medical Announces Hire of Chief Medical Officer
Business Wire - Thu Dec 12, 5:05AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, announced today that Dr. Robert H. Pierce has joined the company as Chief Medical Officer.

OncoSec Medical to Present at the 6th Annual LD Micro Conference
Business Wire - Tue Nov 26, 5:07AM CST
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the Sixth Annual LD Micro Conference.

Exclusive Stock Reports on HIPP, QUAN and ONCS
ACCESSWIRE - Fri Nov 08, 12:32AM CST
Hipcricket Inc (OTC:HIPP), Quantum Internatinal Corp (OTC:QUAN) and OncoSec Medical Inc (OTC:ONCS) have been added to our watch list.

New In Depth Equity Reports on ONCS, DROP and MSLP
ACCESSWIRE - Mon Oct 28, 12:16AM CDT
OncoSec Medical Inc. (PINK: ONCS), Fuse Science, Inc. (OTC: DROP), and MusclePharm Corporation (OTC: MSLP) have been added to our watch list.

OncoSec President and CEO Publishes New Blog Entitled "PD-1 and OncoSec's Combination Study"
ACCESSWIRE - Mon Oct 21, 8:43AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), published a new blog post on The Chairman's Blog, written by the company's President and CEO, Punit Dhillon. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

OncoSec Medical Announces Positive Preliminary Safety Data in Combination Study
Business Wire - Tue Oct 08, 5:05AM CDT
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced positive preliminary animal data demonstrating the benefits of combining the company's ImmunoPulse with anti-CTLA4 and anti-PD1 antibodies.

OncoSec Medical to Present at the 2013 Aegis Capital Healthcare Conference
Business Wire - Fri Sep 20, 5:05AM CDT
OncoSec Medical Inc. (OTCQB:ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy to treat solid tumors, has announced it will be presenting at the 2013 Aegis Capital Healthcare Conference. The presentation will take place at 9:45am PT on Thursday, September 26 at The Encore at Wynn in Las Vegas, NV.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 119

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 284

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 325

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 251

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
s?page=2">More News Articles